Member Info for ojls

Lots of small trades going through with no one making any money at this level. Its a real shame some people cant just sit on their hands as we are starting to look a bit oversold.
The only thing that really stings for me is that my average is considerably higher than the current level so some luck ********** is going to clean up when the price finally heads north.

Its a bit miserable watching the SP sat at this level, however, the trade off is that we see less dilution in the short term as the warrants expire.
Almost a third of the MCAP is covered by our cash reserves (that's something you don't often get with AIM listed entities).
For those buying at this level it appears that they cant lose (anything less than 0.01 is a bit of a bargain with the potential for 3 or 4 times that level on commercialisation of AZD1656).
JN will be fully aware of the SP but is known for only releasing meaningful news so we might not get anything for a week or two but when news does land you can be sure that its good!

The big guns have been out today. I saw at least three trades that were more than a tenner!
Come on JN, bang some news out. The de-ramping and cross promotion of s**t shares is going to kick off again if we have nothing good to talk about.

I don't know about funny. More stupid! Someone has clearly been reading a book about day trading this weekend and misunderstood some key parts :)

Google tells me a string of 1's is good news. Apparently it signifies intuition, insight, and enlightenment.
I don't ordinarily believe in that sort of stuff but I will take what I can in the absence of news to get the SP motoring!

I think you are spot on. SGS are operating as a charity. Private donors wont be keen on dumping cash into them simply to cover debt. Although donations are essentially a gift, donors tend to like the idea that their money will be invested well and help the organisation develop rather than paying off loans etc.
Given the above, they need to get hold of cash asap with the easiest route being the sale of VELA shares (offloaded in one chunk).

Buy more!
Either we get mega news and warrant holders get their conversion or news doesn't arrive in time and existing holders get less dilution.
VELA is valued at the same level as October last year. Everyone who has done more than 5 minutes of research can see why that is wrong!

Good old AIM favouring traders rather than investors.
Its incredibly frustrating and quite frankly a bit of a joke considering the investment in SGS/AZD is massively de-risked vs a month ago.
Come on JN - Show us what you can do. Some us have built sizable holdings that are currently in the red due to a lack of news.

I don't think there is a limit provided the company continues to report finances to the market and operate correctly under LSE rules.
I can tell you one thing for certain - All these extensions are starting to get bl**dy boring!

SP 40% down since the RNS confirming phase 2 trials completed and successful. That's the drop I was expecting if results were bad (given the cash balance and other investments).
Well done to those loading up at this level. I don't see the SP being suppressed for long given the commercialisation RNS is likely only days away.

The SP really doesn't reflect the magnitude of the news both past and future.
I can only assume a few folk are exiting with a small percentage of profit after buying in July/August, although I have no idea why anyone would want out ahead of the RNS confirming what pounds/pence are due to VELA for the 8% stake in the AZD1656 trials.
Phase 3 is pretty much nailed on as an oral treatment for C19 would be a real game changer (Take a look at todays news that 100 million vaccinations will go "out of date" by December). It would be interesting to know whether VELA are interested in/or could take a stake on the phase 3 trials while raking in the cash from AZD1656 treatment for diabetics.

No need to worry about SGS dumping stock in bulk with a portion of the shares going to existing investors who clearly believe in the long game here.
We will be back above 0.1 in no time with commercialisation news likely to have a huge impact

https://www.lse.co.uk/rns/SNT/aeristech-investor-update-9qn7pn9ermmjyc8.html

Its like watching VELA last week. Nice bit of news with an instant positive response followed by a sell off over the following days. SNT is worth 40p all day long with a tiny MCAP. It wouldn't take much buying pressure to fire us north 50% plus again.

10 bagger by Friday!
Sorry I couldn't resist.
I'm off to twitter to tell the world that #VELA is the millionaire maker share of 2021!

https://www.londonstockexchange.com/news-article/CZN/2021-interim-results/15131791

It was clear as day. Dropped on open to try an grab a few stop losses or nervous retail investors. Straight back up in to the 90's in less than an hour.
If you are here solely for AZD1656 then your investment has been massively de-risked. AZ will take the drug back on with news landing pretty sharpish.
If you are here for the long(er) term then JN is delivering on his promises. More income, more cash with bigger and better investments to come.

Looks like a few holders are being robbed early doors today!
Bounce back on the cards once the MMs have extracted a few cheap shares.

I think too many people expected an overnight multibagger. I don't doubt for a second that it could have been the case had the commercials been announced with the trial results, however, lets not forget that JN has many irons in many fires (not just SGS) along with a great stack of cash for future investments.

If you invested because of the AZD1656 trial; simply wait for the value in pounds and pence to arrive for our 8% stake of what so far looks like an effective, affordable and lifesaving drug. That will no doubt see us back north of where we were yesterday by quite some measure.

Perhaps I have misread this but the additional testing would be required for use in the general population. Its could still be licensed/sold in the interim to treat diabetics as that was the purpose of this trial.
Its not unusual for drugs to tested to treat new illnesses despite being on the market for many years.